期刊
CYTOTHERAPY
卷 21, 期 3, 页码 341-357出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jcyt.2018.12.002
关键词
adoptive cell therapy; gene therapy; immunotherapy; T-cell receptor-modified cells
类别
资金
- Medical Research Council
- National Institute for Health Research (NIHR) University College London Hospitals NHS Foundation Trust/University College London (UCLH/UCL) Biomedical Research Centre
- Cancer Research UK (CRUK) Experimental Cancer Medicine Centre
- Bloodwise
- CellMedica
- MRC [G0701703, G0700149, G0902209] Funding Source: UKRI
Immunotherapy constitutes an exciting and rapidly evolving field, and the demonstration that genetically modified T-cell receptors (TCRs) can be used to produce T-lymphocyte populations of desired specificity offers new opportunities for antigen-specific T-cell therapy. Overall, TCR-modified T cells have the ability to target a wide variety of self and non - self targets through the normal biology of a T cell. Although major histocompatibility complex (MHC) - restricted and dependent on co-receptors, genetically engineered TCRs still present a number of characteristics that ensure they are an important alternative strategy to chimeric antigen receptors (CARs), and high-affinity TCRs can now be successfully engineered with the potential to enhance therapeutic efficacy while minimizing adverse events. This review will focus on the main characteristics of TCR gene-modified cells, their potential clinical application and promise to the field of adoptive cell transfer (ACT), basic manufacturing procedures and characterization protocols and overall challenges that need to be overcome so that redirection of TCR specificity may be successfully translated into clinical practice, beyond early-phase clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据